ADMA Biologics
ADMA
95 hedge funds and large institutions have $110M invested in ADMA Biologics in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 39 reducing their positions, and 17 closing their positions.
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
0% more funds holding
Funds holding: 95 → 95 (0)
2.97% less ownership
Funds ownership: 56.51% → 53.54% (-3%)
22% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $2.05M
23% less capital invested
Capital invested by funds: $143M → $110M (-$32.7M)
36% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$4.34M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.86M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$640K |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$599K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$397K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$3.02M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.48M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$2.09M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.21M |
| 5 |
Millennium Management
New York
|
-$798K |
ADMA Hedge Fund Activity: Q3 2020 in Review
95 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2020, worth a combined $110M — down 23% from $143M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ADMA positions and 17 closed out — a net gain of 2 holders — while 25 added to existing stakes and 39 trimmed.
The largest buyer was Marshall Wace, adding an estimated $4.34M. The largest seller was Consonance Capital Management, cutting an estimated $3.02M.
- 95 institutional investors held ADMA Biologics (ADMA) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $110M of ADMA Biologics stock for Q3 2020, down 23% quarter-over-quarter.
- 19 funds opened new ADMA Biologics positions in Q3 2020 and 17 closed out, a net change of +2 holders.
- The largest ADMA Biologics buyer in Q3 2020 was Marshall Wace, an estimated $4.34M added.
- The largest ADMA Biologics seller in Q3 2020 was Consonance Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q3 2020.